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Background. Introduction of cyclosporine (CsA) for clinical use
has greatly enhanced the outcome of organ transplantation.
However, CsA can cause nephrotoxicity and hypertension (HTN).
This study was designed to test the hypothesis that CsA-induced
HTN is related to depressed nitric oxide (NO) production.
Methods. Urinary excretion of NO metabolites (NOx) and
endothelial and inducible NO synthase (eNOS and iNOS) pro-
teins were determined in thoracic aortas and kidneys of CsA-
treated (given CsA 18 mg/kg/day for 3 weeks) and placebo-treated
rats. In addition, renal tissue eNOS and iNOS mRNA and aorta
iNOS activity were measured.
Results. CsA administration resulted in a significant rise in
arterial blood pressure (BP) coupled with a steady decline in
urinary NOx excretion, suggesting depressed NO production. This
was accompanied by a significant reduction in iNOS protein
abundance in the kidney and thoracic aorta but no change in
eNOS protein abundance. The fall in renal iNOS protein in
CsA-treated rats was accompanied by a parallel decline in iNOS
mRNA abundance and enzymatic activity.
Conclusion. Administration of CsA for three weeks resulted in
a significant rise in BP together with marked reductions in urinary
NOx excretion, and renal and vascular iNOS expression. These
observations suggest that CsA-induced HTN may be, in part,
related to impaired NO production. If true, strategies designed to
restore NO availability may mitigate HTN and other vascular
complications of CsA therapy.
Cyclosporine (CsA) is a cyclic neutral peptide of fungal
origin that possesses potent immunosuppressive properties
with practically no bone marrow toxicity. Use of CsA has
greatly enhanced the outcome of organ transplantation and
as such has become the mainstay of the current anti-
rejection regimens [1]. However, CsA administration often
leads to a number of side effects that are primarily circu-
latory and vascular in nature. These include increased renal
and systemic vascular resistance, systemic hypertension
(HTN), microvascular thrombosis, hypercholesterolemia,
and impaired renal function and structure [2–9].
During the past few years, numerous studies have at-
tempted to elucidate the mechanism of CsA-induced HTN
and nephrotoxicity. Much of the initial efforts were di-
rected toward the effects of CsA on vasopressor systems
including catecholamines, renin-angiotensin-aldosterone
system, endothelin, and arachidonic acid metabolites.
While CsA was found to alter either production of or
vascular reactivity to these vasopressors, the findings have
not uncovered a unifying mechanism to account for the
diverse vascular complications of CsA. However, increasing
evidence has emerged pointing to endothelial injury and
dysfunction as the central cause of CsA-induced vascular,
renal and circulatory disorders. In particular, CsA appears
to impair endothelium-dependent relaxation (EDR) in a
variety of in vivo, ex vivo and in vitro models, as well as
vascular preparations of different sizes and functional
characteristics. These include intact animals treated with
CsA [10], aortic rings from CsA-pretreated animals [7,
11–12], normal aortic rings incubated in CsA-containing
media [12], femoral arteries from CsA-pretreated rats,
mesenteric vascular bed perfused with CsA, afferent and
efferent arterioles of the kidneys in CsA-treated rats,
epicardial coronary arteries of CsA-pretreated animals,
and human subcutaneous arterioles challenged with CsA
[12–17].
A number of recent studies point to the L-arginine-NO
pathway as the target for CsA-induced impairment of
endothelium-dependent relaxation. For instance, CsA-in-
duced HTN in both normotensive and spontaneously hy-
pertensive rats can be prevented by supplementing the
animals’ diet with L-arginine [10, 18]. These observations
indicate that CsA-induced impaired vasorelaxation re-
sponse to acetylcholine may be due to decreased NO
production.
The present study was undertaken to examine the effect
of chronic CsA administration on L-arginine-NO pathway
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and expression of endothelial and inducible NO synthase in
the kidney and vascular tissues.
METHODS
Animal models
Male Sprague-Dawley rats (Harlan Sprague-Dawley Inc.,
Indianapolis, IN, USA) with an average weight of 240 g
were used. They were randomly assigned to either a CsA
group or a placebo-treated control group. A minimum of
twelve rats were included in each group. Animals were kept
in a climate-controlled light-regulated space with 12-hour
light ($500 lux) and 12-hour dark (,5 lux) cycles. They
were allowed free access to a low-nitrate basic diet (Purina
Mills, Brentwood, MO, USA) and water. Animals in the
CsA group received 18 mg/kg/day of cyclosporine (Sandoz
Inc., East Hanover, NJ, USA) in olive oil by gastric gavage
for three weeks. The control group received the vehicle
instead.
Arterial blood pressure was monitored regularly using a
tail blood pressure monitor (Harvard Apparatus, South
Natick, MA, USA). On each occasion the animal was
placed on a heating pad, and a tail cuff was placed and
inflated several times to allow the animal to become
accustomed to the procedure. Blood pressure was then
measured and recorded thrice, and the average of the three
values was used.
Five-hour urine collections were obtained over dry ice at
baseline and on days 7, 14 and 21 using individual meta-
bolic cages. On each occasion blood samples were drawn by
orbital sinus puncture. The procedure was carried out
under general anesthesia using pentobarbital, 50 mg/kg i.p.
The blood samples were immediately centrifuged, plasma
separated and frozen at 270°C until processed.
At the conclusion of the three-week treatment period,
animals within each group were divided into two subgroups.
One subgroup was used for infusion experiments while the
other was used for measurements of renal and thoracic
aorta NO synthase (NOS) isotypes. After general anesthe-
sia with i.p. pentobarbital (50 mg/kg), the latter animals
were killed by decapitation between the hours of 9 and
11 a.m. Thoracic aorta and kidneys were harvested imme-
diately, cleaned with PBS, snap-frozen in liquid nitrogen
and stored at 270°C until processed.
Hematocrit, creatinine and creatinine clearance were
determined using standard laboratory methods. All exper-
iments had been approved by the Institutional Animal Care
and Use Committee of the University of California, Irvine.
Response to L-arginine, L-NMMA and sodium
nitroprusside
Under general anesthesia with inactin (100 mg/kg, i.p.),
the left jugular vein and carotid artery were cannulated
with polyethylene tubings (PE50). A tracheal cannula was
also inserted. Rats were then placed on heating pads.
Arterial blood pressure was monitored directly via the
arterial catheter which was connected to a Gould P-50
pressure transducer and recorded on a Dynograph R511A
recorder (Sensor Medics, Anaheim, CA, USA). Once
stable, blood pressure was recorded for five minutes to
determine the baseline value. Subsequently, the hypoten-
sive response to bolus injections of NO precursor, L-
arginine (100 mg/kg; Sigma Chemical Co., St. Louis, MO,
USA) and NO-donor, sodium nitroprusside (SNP, 0.5
mg/kg; Sigma Chemical Co.), was determined. This was
followed by bolus injections of L-NMMA (10 mg/kg; Sigma
Chemical Co.), a competitive inhibitor of NO synthase.
Response to each drug was calculated as peak change in
blood pressure from baseline. Mean arterial pressure
(MAP) was calculated as the sum of diastolic blood pres-
sure and one-third of the pulse pressure. Each drug was
injected at least twice, and the average of the values
obtained was used. A thirty-minute recovery period was
allowed after each bolus injection except for the L-NMMA
injections, which were sixty minutes apart.
RNA isolations
Kidney specimen for analysis of RNA was immediately
frozen in liquid nitrogen and then stored at 270°C. Frozen
kidney was homogenized by a polytron homogenizer (Ki-
nematica AG, Littau, Switzerland). Total RNA was puri-
fied by TRI reagent from Molecular Research Center Inc.
(Cincinnati, OH, USA). The total RNA concentration in
each sample was determined from absorbance at 260 nm.
The quality of each RNA preparation was determined by
1% agarose-formaldehyde gel electrophoresis and ethidium
bromide staining.
Northern blot analysis
Twenty micrograms of total RNA were loaded into each
lane of 1% agarose-formaldehyde gel. Electrophoresis was
carried out at 4 volts per cm gel length. The RNA from the
gel was transferred onto positively charged Hybond nylon
membrane (Amersham Life Science, Arlington Heights,
IL, USA) by capillary transfer. The nylon membrane was
UV cross-linked using a UV cross-linker (Fisher Scientific,
Pittsburgh, PA, USA). The cDNA clones for rat endothe-
lial eNOS (324 bp) and inducible iNOS (1500 bp) were
generously provided by Dr. Thomas Michel (Harvard Med-
ical School, Boston, MA, USA) and Dr. Robert Star
(Southwestern Medical Center, Dallas, TX, USA), respec-
tively. The clone for eNOS was linearized by a restriction
endonuclease XbaI while the iNOS clone was linearized
with KPN (Pharmacia Biotech Inc., Piscataway, NJ, USA).
The antisence cRNA of eNOS was generated with T7 RNA
polymerase (Ambion Inc., Austin, TX, USA), and the
antisence cRNA for iNOS was generated by T3 RNA
polymerase (Ambion Inc.). The blots were hybridized using
a[32p] cytidin triphosphate-labeled eNOS and iNOS ribo-
probes. The membranes were washed four times in 20
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minutes, twice in 2 3 SSC with 0.1% SDS at room
temperature and twice in 0.1 3 SSC with 0.5% SDS at
65°C. Autoradiography was performed by exposing the
blots to x-ray film (Reflection; NEN Research Products,
Boston, MA, USA) with intensifying screens at 270°C. An
internal standard of b-actin cDNA probe (Clontech Labo-
ratories Inc., Palo Alto, CA, USA) was used to assess RNA
loading. Quantitation of mRNA signals was performed by
densitometric scanning of autoradiographs (Molecular Dy-
namics, Sunnyvale, CA, USA). The eNOS and iNOS
signals were standardized against the b-actin signal for each
sample, and the results were expressed as eNOS/b-actin
and iNOS/b-actin ratios.
Tissue preparation
Thoracic aorta and kidney were used for determination
of NO synthase (NOS). Rats were sacrificed by decapita-
tion, and thoracic aorta and kidney were immediately
excised, cleaned with PBS, frozen in liquid nitrogen and
stored at 270°C. Homogenates (25% wt/vol) were pre-
pared in 10 mM HEPES buffer, pH 7.4, containing 320 mM
sucrose, 1 mM EDTA, 1 mM DTT, 10 mg/ml leupeptin and
2 mg/ml aprotinin at 0 to 4°C with the aid of a tissue grinder
fitted with a motor-driven ground glass pestle. Homoge-
nates were centrifuged at 12,000 g for five minutes at 4°C to
remove tissue debris without precipitating plasma mem-
brane fragments [19, 20]. The supernatant was used for
determination of NOS activity and protein mass. Protein
concentration was determined by using a Bio-Rad kit
(Bio-Rad Laboratories, Hercules, CA, USA).
Nitric oxide synthase activity assay
Calcium-independent NOS activity was measured as
previously described. [21] In brief, 40 ml of the homoge-
nates (approximately 200 mg protein) were incubated in a
buffer (Tris-HCl [50 mM], EDTA [1.7 mM], and EGTA [0.1
mM]) containing cofactors (calmodulin [10 mM], tetrahydro-
biopterin [3 mM] and NADPH [1 mM]) and the substrate,
L-arginine 100 mM, combined with L-[3H]-arginine (0.2 mCi;
sp at 55 Ci/mmol) for 45 minutes at 37°C. The mixture also
contained 1 mM L-citrulline to minimize conversion of
newly formed L-[3H]-citrulline back to L-[3H]-arginine. Af-
ter the incubation period, the reaction was quenched by
addition of 1 ml of stop buffer [HEPES (20 mM), pH 5.5,
EDTA (2 mM), and EGTA (2 mM)]. The reaction mix was
applied to a 1-ml column containing Dowex AG 50-WX8
(Na1 form) resin that had been pre-equilibrated with the
stop buffer. L-[3H]-citrulline was eluted twice with 0.5 ml of
stop buffer, and radioactivity was determined by liquid
scintillation counting. Protein concentration of the homog-
enates was determined by using a Bio-Rad kit with bovine
albumin used as the standard.
Western blot analysis
These measurements were carried out to determine the
endothelial and inducible NOS (eNOS and iNOS) protein
mass as previously described [19, 20]. Anti-eNOS monoclo-
nal antibody, peroxidase-conjugated goat anti-mouse IgG
antibody, anti-Mac NOS-I, human endothelial positive
control and mouse macrophage positive control were sup-
plied by Transduction Laboratories (Lexington, KY, USA).
Briefly, aorta and kidney tissue preparations (50 mg of
protein for the aorta and 100 mg for the kidney) were
size-fractionated on 4 to 12% Tris-glycine gel (Novex, San
Diego, CA, USA) at 120 V for three hours. In preliminary
experiments we had found that the given protein concen-
trations were within the linear range of detection for our
Western blot technique. After electrophoresis, proteins
were transferred onto hybond-ECL membrane (Amersham
Life Science Inc., Arlington Heights, IL, USA) at 400 mA
for 120 minutes using the Novex transfer system. The
membrane was prehybridized in 10 ml of buffer A (10 mM
Tris hydrochloride, pH 7.5, 100 mM NaCl, 0.1% Tween 20
and 10% nonfat milk powder) for one hour and then
hybridized for an additional one-hour period in the same
buffer containing 10 ml of the given anti-NOS monoclonal
antibody (1:1000). The membrane was then washed for 30
minutes in a shaking bath, changing the wash buffer (buffer
A without nonfat milk) every five minutes prior to one hour
of incubation in buffer A plus goat anti-mouse IgG-HRP
(horse radish peroxidase) at the final titer of 1:1000.
Experiments were carried out at room temperature. The
washes were repeated before the membrane was developed
with a light emitting nonradioactive method using ECL
reagent (Amersham Inc.). The membrane was then sub-
jected to autoluminography for one to five minutes. The
autoluminographs were scanned with a laser densitometer
(Model PD1211; Molecular Dynamics, Sunnyvale, CA,
USA) to determine the relative optical densities of the
bands. In all instances, the membranes were stained with
Ponceau stain which verified the uniformity of protein load
and transfer efficiency across the test samples.
Measurements of total nitrate and nitrite
The concentration of total nitrate and nitrite (NOx) in
the test samples was determined as described previously
[22] using the purge system of a Sievers Instruments Model
Table 1. Body weight, hematocrit (Hct), serum creatinine (SCr)
concentration and creatinine clearance (CCr) obtained at the beginning
and the end of the study in the cyclosporine-treated (CsA) and placebo-
treated control rats
Control group CsA group
Initial Final Initial Final
Body weight g 237 6 4.7 367 6 6.3a 243 6 2.3 319 6 7.6a,b
Hct % 44.4 6 1.1 43.4 6 1.2 45 6 1.5 43.7 6 1.9
SCr mg/dl 0.48 6 0.01 0.45 6 0.01 0.43 6 0.02 0.51 6 0.01
a,b
CCr ml/min 1.1 6 0.1 1.66 6 0.2
a 1.16 6 0.02 1.43 6 0.1a
N 5 12 in each group.
a P , 0.05 vs. initial
b P , 0.05 vs. corresponding value in the control
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270B Nitric Oxide Analyzer (NOAy; Sievers Instruments
Inc., Boulder, CO, USA). Briefly, urine samples were
diluted ten times in distilled water prior to analysis. A
saturated solution of VCl3 in 1 M HCl was prepared and
filtered prior to use. Five milliliters of this reagent were
added to the purge vessel and purged with nitrogen gas for
5 to 10 minutes prior to use. The purge vessel was equipped
with a cold water condenser and a water jacket to permit
heating of the reagent to 95°C using a circulating water
bath. The hydrochloric acid vapors were removed by a gas
bubbler containing ;15 ml of 1 M NaOH. The gas flow rate
into the chemiluminescence detector was controlled using a
needle valve adjusted to yield a cell pressure of ;7 torr.
The flow rate of nitrogen into the purge vessel was adjusted
to prevent vacuum distillation of the reagent.
Samples were injected into the purge vessel to react with
the VCl3/HCl reagent which converted nitrate, nitrite and
S-nitroso compounds to NO. The NO produced was
stripped from the reaction chamber (by purging with
nitrogen and vacuum) and detected by ozone-induced
chemiluminescence in the chemiluminescence detector.
The signal generated (NO peak and peak area) was re-
corded and processed by a Hewlett Packard Model 3390
Integrator. In a typical assay, 5 ml of the test sample were
injected to the purge vessel, and all samples were run in
triplicate.
Standard curves were constructed using various concen-
trations of NO3
2 (5 to 100 mM) relating the luminescence
produced to the given NO3
2 concentrations of the standard
solutions. The amount of NO2
2/NO3
2 in the test sample
was determined by interpolation of the result into the
standard curve.
Data analysis
Analysis of variance (ANOVA) and a t-test were used in
evaluation of the data which are presented as mean 6 SEM.
P values less than 0.05 were considered significant.
RESULTS
General data
Data are shown in Table 1 and Figure 1. The CsA group
showed a significantly lower body wt, a slight but signifi-
cantly higher serum creatinine concentration, and a slight
and insignificantly lower creatinine clearance at the conclu-
sion of the study when compared with the placebo-treated
control group. Hematocrit values in the CsA group were
comparable with those found in the control group. As
expected, the CsA-treated animals exhibited a significant
rise in arterial blood pressure during the study period. In
contrast, blood pressure remained virtually unchanged in
the placebo-treated control animals.
Response to L-arginine, L-NMMA and nitroprusside
Data are illustrated in Figure 2. The CsA and normal
control animals exhibited a transient fall in arterial blood
pressure within a few seconds after the bolus injection of
L-arginine. However, the magnitude of hypotensive re-
sponse to L-arginine in the CsA group was significantly less
than that seen in the control group (P , 0.05).
L-NMMA administration resulted in a rise in arterial
blood pressure lasting ten to twenty minutes in the two
groups. However, the hypertensive response to L-NMMA
was greatly reduced in the CsA group as compared to that
seen in the control group (P , 0.01). In contrast to
L-arginine and L-NMMA, the magnitude of hypotensive
response to NO-donor sodium nitroprusside was similar in
the two groups.
Urinary nitrate/nitrite (NOx) data
Data are depicted in Figure 3. CsA administration
resulted in a significant and steady reduction in urinary
Fig. 1. Measurements of systolic arterial blood pressure in the cyclospor-
ine-treated (CsA; f) and vehicle-treated control (CTL; F) animals. N 5
6 in each group. *P , 0.05. **P , 0.01 versus both baseline and control
values.
Fig. 2. Change in arterial blood pressure in response to intravenous
administrations of L-arginine, NG monomethyl-L-arginine (L-NMMA) and
sodium nitroprusside (SNP) in cyclosporine-treated (f) and vehicle-
treated control (M) animals. N 5 6 in each group. *P , 0.05, **P , 0.01
versus control group.
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NOx excretion during the study period. In fact, urinary
NOx excretion fell by 33% after one week and 62% after
three weeks of CsA therapy in the CsA group. In contrast,
urinary NOx excretion remained unchanged in the placebo-
treated control group.
Kidney and aorta nitric oxide synthase data
Data are illustrated in Figures 5 to 11. The CsA group
showed a nearly threefold reduction in the aorta iNOS
protein abundance as compared to the normal control
group (P , 0.05). The reduction in the aorta iNOS protein
abundance was accompanied by a parallel decline in Ca21-
independent NOS activity, which signifies depressed iNOS
enzymatic activity. However, no significant difference was
found in the aorta eNOS abundance between the two
groups. As with the aorta, kidney tissue iNOS protein
abundance was significantly reduced in the CsA groups
when compared with that found in the control group (P ,
0.05). The reduction in renal tissue iNOS abundance was
accompanied by a parallel reduction in kidney iNOS
mRNA abundance. No significant difference was found in
renal tissue eNOS protein abundance between the CsA and
the control groups. Likewise, kidney tissue eNOS mRNA
abundance was similar in the two groups.
DISCUSSION
The CsA-treated animals employed in the present study
exhibited an expected rise in arterial blood pressure. The
rise in arterial blood pressure in the CsA group was
accompanied by a steady decline in urinary NOx excretion,
suggesting a possible decline in total body NO production
during the study period. In addition, the CsA-treated
Fig. 3. Urinary excretion of total nitrate and nitrite (NOx) in the
cyclosporine-treated (f) and vehicle-treated control (M) groups. N 5 6 in
each group. *P , 0.05 versus control group. Fig. 4. Correlation between urinary excretion of total nitrate and nitrite
(NOx) and systolic blood pressure in the cyclosporine-treated (f) and
vehicle-treated control (F) animals (r 5 20.78; P < 0.05; N 5 6 in each
group.
Fig. 5. (A) Representative Western blot of aorta iNOS protein in three
vehicle-treated (CTL) and three cyclosporine-treated (CsA) rats. (B)
Group data depicting relative optical densities of aorta iNOS protein
bands in the CTL (M) and CsA (f) groups. N 5 6 in each group. *P ,
0.05 versus control group.
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animals showed an attenuated hypotensive response to
L-arginine but a normal response to NO-donor, nitroprus-
side. The impaired response to NO-substrate despite nor-
mal response to exogenous NO suggests that NO synthesis
from L-arginine may be diminished in CsA-treated animals.
This supposition is supported by significant reduction in
vascular and renal tissue expression of iNOS protein in the
CsA group. The reduction in kidney tissue iNOS protein in
the CsA-treated animals was accompanied by a parallel
decline in renal tissue iNOS mRNA abundance. This
observation suggests that down-regulation of iNOS in the
CsA-treated rats occurs at the level of mRNA. Interest-
ingly, CsA therapy under the given conditions had no
discernible effect on eNOS expression in either the kidney
or thoracic aorta. It should be noted that the normality of
eNOS protein mass shown here does not contradict the
reported inhibitory effect of CsA on eNOS enzymatic
activity [23]. The latter is due to interference of CsA with
Ca-calmodulin-dependent activation as opposed to quanti-
tative modification of eNOS [23]. Consequently, the reduc-
tion in urinary NOx excretion and attenuated response to
L-arginine in CsA-treated animals could be due to a
combination of iNOS deficiency shown here and eNOS
inhibition shown by Hutcheson et al [23]. These investiga-
tors recently demonstrated a marked inhibition of NOS
activity of the 100,000 g fraction of the rat heart by CsA at
a wide range of drug concentrations. This observation
suggests that CsA is a direct inhibitor of eNOS [23].
Likewise, these investigators found that CsA inhibited
Ca21 ATPase activity of the rat heart preparation in vitro.
Based on these observations, the authors concluded that
inhibition of the two Ca21-calmodulin-dependent enzymes
may be due to the drug’s interference with Ca21-calmodu-
lin-mediated events.
Diminished hypertensive response to NOS inhibitor,
L-NMMA, in our animals further supports the notion that
NO generation is impaired and that contribution of NO to
blood pressure homeostasis is reduced in CsA-treated
animals. This viewpoint is supported by earlier studies
demonstrating that the inhibitory action of methylene blue
(a potent NO quencher) on acetylcholine-mediated vaso-
dilation was greatly reduced in CsA preincubated mesen-
teric resistance vessels as compared to the untreated tissues
[13]. Additional indirect evidence for diminished NO pro-
duction comes from studies by Rego et al which demon-
strated that CsA treatment lowers the aorta content of
Fig. 6. (A) Representative Western blot of aorta eNOS protein in three
vehicle-treated control (CTL) and three cyclosporine-treated (CsA) rats.
(B) Group data illustrating the optical densities of aorta eNOS protein
bands in the CTL (M) and CsA (f) groups. N 5 6 in each group.
Fig. 7. (A) Representative Western blot of kidney tissue eNOS protein in
three vehicle-treated (CTL) and three cyclosporine-treated (CsA) rats.
(B) Group data depicting relative optical densities of kidney eNOS protein
bands in the CTL (M) and CsA (f) groups. N 5 6 in each group.
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cGMP, the second messenger of NO in vascular smooth
muscle [12].
Renal production of NO plays an important role in
regulation of renal vascular resistance as well as sodium
and water transport in the renal tubules [24–30]. For
instance, NOS blockade leads to afferent arteriolar vaso-
constriction [31, 32], reduced urinary sodium excretion
[33–35], and blunted pressure natruresis [36–39]. In con-
trast, administration of NO-donor lowers blood pressure
and promotes natruresis [40]. In addition, impaired vascu-
lar NO production necessarily raises systemic vascular
resistance by reducing the vasodilatory tone. Thus, by
raising renal and systemic vascular resistance and by pro-
moting sodium retention, inhibition of L-arginine-NO path-
way can lead to arterial hypertension. Our CsA-treated
animals showed a marked reduction in urinary NOx excre-
tion, suggesting depressed renal and systemic NO produc-
tion. This proposition was supported by the significant
reductions in renal and vascular tissue iNOS protein ex-
pression shown here and the potent inhibitory action of
CsA on eNOS activity shown by Hutcheson et al [23]. It is
thus logical to assume that the CsA-induced HTN in this
model is, at least, in part, caused by NO deficiency. Given
the well-known inhibitory action of NO on platelet adhe-
sion/aggregation, NO deficiency can theoretically contrib-
ute to microvascular thrombosis associated with CsA tox-
icity as well [41]. Thus, inhibition of L-arginine-No pathway
can account for several adverse effects of CsA therapy. If
true, strategies designed to correct NO deficiency may
prove useful in preventing the adverse effects of CsA and
other drugs capable of interfering with L-arginine-NO
pathway.
The mechanism(s) responsible for down-regulation of
iNOS protein in the CsA-treated animals is uncertain. It is
of note that contrary to the original views, iNOS is consti-
tutively expressed in a few organs. For instance, in the
kidney iNOS is abundantly expressed in the medullary thick
ascending limb of loop of Henle, glomeruli, as well as
interlobular and arcuate arteries at basal conditions [42–
44]. In fact, we have recently shown constitutive expression
of iNOS in the kidney and vascular tissues of untreated
intact Sprague Dawley rats, Wistar Kyoto rats and sponta-
neously hypertensive rats (SHR), and its altered expression
in various disease states [45–47]. In this regard, we have
Fig. 8. (A) Representative Western blot of kidney tissue iNOS protein in
three vehicle-treated (CTL) and three cyclosporine-treated (CsA) rats.
(B) Group data depicting relative optical densities of kidney iNOS protein
bands in the CTL and CsA groups. N 5 6 in each group. *P , 0.05 versus
control group.
Fig. 9. (A) Northern blots of the kidney tissue eNOS and b-actin mRNA
in four normal control (CTL) and four cyclosporine-treated (CsA) rats.
(B) Group data illustrating renal tissue eNOS/b-actin mRNA abundance
in CTL (M) and CsA (f) animals. No significant difference was found
between the two groups.
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found up-regulation of iNOS and eNOS in the SHR [45],
up-regulation of iNOS but not eNOS in rats with lead-
induced hypertension [46], and down-regulation of both in
rats with chronic renal insufficiency [47]. The constitutive
expression of iNOS in the kidney and other structures
suggests its possible role in some homeostatic function in
these tissues. While low level expression occurs constitu-
tively in the kidney and certain other tissues, maximum
expression of iNOS requires induction by a specific combi-
nation of lipopolysaccharide or cytokines.
The CsA animals were treated with oral administration
of the drug by gavage. In a pharmacokinetic study, He-
dayati, Bernareggi and Rowland demonstrated that 24% of
orally administered CsA in olive oil, given by gavage, was
absorbed within five hours in the rat. They further found
that the absorption ceased after five hours and was unaf-
fected by rat chow [48]. Although we did not study the
pharmacokinetics of CsA in the present study, we assume
that the general observations reported by these authors
may be applicable to the rats employed in the present study.
In an earlier study Rao et al reported increased NOS
enzymatic activity in the kidneys of rats treated with CsA
for four weeks. In addition, they found increased NOS
activity of the normal kidneys in the presence of CsA in
vitro [49]. They concluded that this phenomenon may be
due to alteration of calcium-calmodulin dependent activa-
tion of NOS by CsA [49]. In contrast, we found diminished
iNOS protein together with decreased urinary NOx excre-
tion in the CsA-treated rats suggesting impaired NO pro-
duction. The reason for the apparent disparity between the
results of this study and those of Rao et al is unclear. It is
of interest that in another study, Hutcheson and Rao et al
showed a marked inhibition of cardiac tissue NOS activity
with CsA in vitro [23]. They suggested that the observed
inhibitory effect of CsA may be due to interference of CsA
with calcium-calmodulin dependent activation of NOS [23].
Thus, in the latter study in which Dr. Rao was a co-author,
CsA had an inhibitory action on cardiac NOS [23], whereas
in the former study by Rao et al, CsA was found to have a
stimulatory effect on NOS [49]. Given the fact that calcium-
calmodulin dependent activation of constitutive NOS iso-
types is similar in all tissues, we found the disparity between
the two studies by these authors somewhat puzzling. It is of
note that abundance in the kidney of arginase, an enzyme
that like NOS utilizes L-arginine as it substrate, constitutes
a major difficulty in assessing the true NOS activity in this
organ. For this reason, we abandoned the measurement of
NOS enzymatic activity in the kidney. Instead, we used
direct measurements of the enzyme protein mass and
urinary NOx excretion in our studies. It is conceivable that
the apparent increase in NOS activity of the kidney with
CsA reported by Rao et al may have been an artifact of
CsA interaction with the renal arginase activity. Further
studies are required to explore the latter possibility.
Fig. 10. (A) Northern blots of the kidney tissue iNOS and b-actin mRNA
in four normal control (CTL) and four cyclosporine-treated (CsA) rats.
(B) Group data illustrating renal tissue iNOS/b-actin mRNA abundance
in CTL (M) and CsA (f) animals. *P , 0.01.
Fig. 11. Aorta tissue iNOS (Ca21-independent) activity in six cyclospor-
ine-treated (CsA; f) and six normal control (CTL; M) rats. *P , 0.001.
Vaziri et al: Down-regulation of NO synthase by cyclosporine 489
In conclusion, CsA administration for three weeks re-
sulted in a significant increase in arterial blood pressure in
genetically normotensive Sprague Dawley rats. This was
accompanied by a marked reduction in urinary nitrate/
nitrite excretion together with marked down-regulation of
renal and vascular expression of iNOS but not eNOS. The
observed down-regulation of iNOS shown here together
with CsA-induced inhibition of eNOS enzymatic activity
shown by others can account for the reduction in NO produc-
tion in the CsA-treated animals. If true, depressed NO
production can contribute to CsA-induced hypertension.
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